Home

VISION

Integrate most effective treatments for wound healing into a single dressing, overcoming limitations of each and setting new standards in advance wound care.

ABOUT US

Imbed Biosciences, Inc, (“Imbed”) is a privately held medical device company developing novel and patent-pending technologies for imbedding bioactive molecules in wound dressings and surgical implants. By leveraging its novel biomaterials platforms, Imbed is revolutionizing wound dressings to prevent wound infections and expedite wound closure, and ideally reduce the overall cost of managing surgical and chronic wounds, a $3 billion market opportunity in the U.S. and Europe. Imbed is a spin-off from the University of Wisconsin-Madison, based on 4 years of research by a multidisciplinary group of engineers, veterinary scientists and medical surgeons. Collectively, the founders bring more than 25 years of experience in clinical wound management.

PRODUCTS

Our first product platform is antibacterial silver nanofilms. Conventional technologies are limited in their ability to incorporate silver within delicate biologic dressings because of the involved corrosive chemical processing. The revolutionary advance in our platforms is in their ability to surface engineer biologic dressings and surgical implants with antibacterial silver without exposing the dressings to chemical processing.

The nanofilms platform also allows biologic dressings to provide long-term (several days/weeks) release of antibacterial but non-toxic silver in wounds, circumventing frequent painful dressing changes while reducing toxicity concerns with silver. Overall, this technology promises to prevent wound infections under biologic dressings in a more efficient way and improve patient healing. Safety and efficacy of our silver nanofilms is being tested on several dressing types in animal wound models.

ECONOMIC AND HEALTHCARE IMPACT

Wound management presents a huge economic and healthcare burden in the U.S.  Chronic wounds such as diabetic ulcers or pressure sores affect 6.5 million patients in the U.S. and another 2.1 million seek medical care for burns, seeking critical care to prevent infections. In addition, infection following surgery occurs in up to 5% of cases in the U.S., causing delayed healing, prolonged hospital stays, patient suffering and increased treatment costs. Conventional approaches to treat wounds require frequent painful dressing changes or result in bacteria resistant to antibiotics.

Based on the clinicians feedback, we are developing a new class of advanced wound dressings resistant to infections that combine the benefits of antimicrobial and bioactive wound modulating factors.  The new dressings would prevent infections and actively promote tissue growth to expedite wound closure. They will reduce use of antibiotics, minimize dressing changes and nurse time, and lower patient pain, medication costs and length of hospital stays.